Your Dose of Cannabis Education

Your Dose of Cannabis Education

Only have a minute but want to Learn something every day? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.

Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education

Wake up every morning and get your dose of unbiased evidence-based cannabis education!

Bennabis Health

We’re making medical cannabis
more affordable and
understandable!

Use code BENNABISHEALTH to save 20% on any CME Course.

Visit the Bennabis Health website.

2025-07-01
The effects of cannabinoids are dependent upon the route of administration, the health of the consumer and other factors. There is also interindividual variation. Provide some reasons why the effects of cannabinoids vary among individuals.
There are many reasons why the effects of cannabinoids vary among individuals. SOME of the reasons are: diet, age, health of the patient, and co-administered medications may impact metabolism and efficacy of cannabinoid-based products. Also, some patients have a genetic profile such that they are predisposed to experience side effects (for ex., exacerbation of a psychotic disorder/schizophrenia) after exposure to THC. In addition, patients that have been consuming cannabinoid-based products long-term react differently than patients who have never consumed cannabinoid-based products.
Grotenhermen F. Clinical pharmacokinetics of cannabinoids. J Cannabis Ther, 2003; 3(1): 3-51. https://www.tandfonline.com/doi/abs/10.1300/J175v03n01_02. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518/
2025-06-30
Even if an individual employs the same mode of administration over time, the effects of cannabinoids may change for that individual. Provide some reasons why this may be so.
The effects of cannabinoids may change over time due to multiple factors, including: 1. tolerance to the cannabinoids may develop 2. change in the patient's health status/ medical condition may change over time and lead to physiological changes in the endocannabinoid system (For example, inflammation impacts the ECS. Also, impaired G.I./liver function affects the absorption and metabolism of cannabinoids.) 3. The patient may start or stop taking a medication that interacts with cannabinoids or affects the metabolism of the cannabinoid-based product. 4. Physiologic changes in the endocannabinoid system take place as patients age.
Grotenhermen F. Clinical pharmacokinetics of cannabinoids. J Cannabis Ther, 2003; 3(1): 3-51. https://www.tandfonline.com/doi/abs/10.1300/J175v03n01_02 Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518/
2025-06-27
Some patients use cannabinoid-based medicines to treat nausea and vomiting. Is one of the side effects of cannabinoid-based medicines nausea and vomiting?
Yes.. The adverse event profile of cannabinoid-based formulations is dependent upon the ratio of CBD:THC, the presence of other cannabinoids and terpenes, and the dose consumed. The known common adverse effects of cannabinoid-based medicines include sedation/somnolence, dizziness, anxiety, cognitive dysfunction, nausea, vomiting, diarrhea, vertigo, increased or decreased appetite and dry mouth.
Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther. 1996 Oct;34(10)446-52. https://pubmed.ncbi.nlm.nih.gov/8897084/
2025-06-26
How should a clinician monitor the outcome of cannabinoid-based therapy?
As suggested by the Australian Centre for Cannabinoid Clinical and Research Excellence, monitoring should initially involve reviewing the patient weekly in person, and via phone if required in the interim between clinical reviews. "There are three areas of outcomes that should be considered: 1. Symptom control - "A pre-defined measure of success should be negotiated with the patient prior to commencement of therapy. This can be measured by using a validated tool, for example by the Palliative Care Symptom Assessment Scale. " 2. Drug adverse events - "Careful monitoring of patients for adverse events and the need for a change in dosage is important. Adverse events may become apparent after commencement or after change in dose...Adverse events may be related to other concurrent medications. Doses of these medicines should be adjusted as appropriate. " 3. Pathology monitoring - "Drug concentrations of drugs where there is a potential or actual drug-drug interaction may be important. Cannabidiol may cause hepatocellular injury. Patient’s liver function biochemistry should be monitored prior to initiation and periodically as clinically indicated."
Prescribing Cannabis Medicines for Chronic Non-cancer Pain v2 September 2019 c10. - by the Australian Centre for Cannabinoid Clinical and research Excellence https://www.ces.edu.co/wp-content/uploads/2020/09/acre-prescribing-guidance-chronic-non-cancer-pain.pdf
2025-06-25
How long should the testing period of a cannabinoid-based drug be?
According to the European Pain Federation position paper on the appropriate use of cannabis-based medicines, a testing period of maximum 3 months should be considered both by patients and prescribers [or recommenders], to assess treatment efficacy and safety. At the end of this testing period, long_term treatment should only be considered with significant improvement and lack of safety issues.If a satisfactory outcome is achieved, the patient should remain under close medical surveillance for the duration of cannabis_based medicine therapy If the predefined treatment goals are not achieved and/or unacceptable burden of side effects occur and/or signs of abuse and misuse are observed, the specific cannabis_based medicines should be safely withdrawn and alternative options actively explored.
Huser, W, Finn, DP, Kalso, E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis_based medicines and medical cannabis for chronic pain management. Eur J Pain.. 2018; 22: 1547Đ 1564. https://pubmed.ncbi.nlm.nih.gov/30074291/

Learn something every day in your feed…

Follow @The_Answer_Page

New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.